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patients included in these studies was 118 patients (min: 30, max: 724). On average,
median PFS/TTP was 14.0 months (sd12.4) and median OS was 35.0 months
(sd31.2). Results of the correlation analysis indicated that median PFS/TTP is
highly correlated with median OS, with a Spearman’s correlation coefficient of
0.813 (p0.001). A significant correlation between median PFS/TTP and median OS
was observed in the second-line and subsequent-line therapies, but not in the
first-line setting. CONCLUSIONS: The present results demonstrate a very strong
correlation between median PFS/TTP and median OS in the context of CLL, which
reinforce the hypothesis that PFS/TTP would be adequate surrogate endpoints for
OS in this cancer setting.
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OBJECTIVES: Survival is a key index of the overall effectiveness of health services
in the management of patients with cancer. Epidemiological data on cancer sur-
vival in unselected patient populations in Europe are sparse and incomplete. Prog-
nosis is directly related to staging of cancer at diagnosis. Our objective is to evaluate
variations in survival by using country registry data and published population-
based studies for six tumors: lung, bladder, colorectal, ovarian, pancreatic and
gastric.METHODS:Cancer data from nine registries (in France, Italy, Germany, The
Netherlands, Austria, Norway, Ireland, Finland, UK) in Europe were used along with
literature review using Embase for the period 2000-2012. Relative survival (RS) es-
timates for various time periods were summarized for stage III and IV for each
tumor type. RESULTS: Marked differences in population based survival across Eu-
rope were found which could be explained in part by variation in terms of time
period and staging definition but also by other factors such as clinical practice,
histological type, age, death ascertainment and co-morbidities. 5-year relative sur-
vival (RS) in stage III varies greatly according to tumor site with improvement
observed over time. 5-year RS rates ranged from 4-24% for lung, 20-45% for bladder,
40-66% for colorectal, 20-61% for ovary, 8% for pancreas and 13-35% for gastric.
Survival in metastatic cancer remains low. 1 year RS rates for Stage IV cancers were
7-38% for lung, 24-56% for bladder, 19-81% for colorectal, 34-77% for ovary, 6-16%
for pancreas and 6-34% for gastric. CONCLUSIONS: Variations of survival in unse-
lected patient populations are due to differences in patient characteristics, diag-
nostic codification, and treatment modalities. Future work should validate these
findings as registry data is inherent with limitations such as variation in follow up
time periods, disease coding and definition of survival. More efforts should focus
on standardization of data capturing processes across European cancer registries.
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OBJECTIVES: Vinorelbine in non-small lung cancer treatment was not available in
Croatia through the Croatian National Health Insurance (CNHI) Positive Drugs List
(PDL). The aim of our study was to analyse a possible impact of vinorelbine inclu-
sion to the CNHI PDL according to the budget impact analysis (BIA). METHODS: A
clinical guideline for vinorelbine reimbursement by CNHI is proposed according to
evidence-based medical criteria and international guidelines. We have calculated
the number of patients, potential candidates for vinorelbine treatment, and we
have also developed BIA model for three-years period after the drug reimburse-
ment. The share of vinorelbine has been estimated using market data from other
countries and the price of vinorelbine has been calculated according to the Croa-
tian MoH Pricing Ordinance. The total costs for CNHI have been calculated using a
referent scenario (without vinorelbine) and a scenario with vinorelbine reimburse-
ment. Monte Carlo simulation has been performed too.RESULTS:The total number
of patients in non-small cell lung cancer stage III and IV is estimated to be 500-550
per year. Referent treatment costs are between 1,705 EUR and 10,974 EUR per pa-
tient (in case of biological treatment usage). Vinorelbine costs are 1,044 EUR (mono-
therapy) and 1,407 EUR (combination with cisplatin). Monte Carlo simulation
showed annual cost of 1,266,794 EUR in scenario without vinorelbine and declining
costs in scenario with vinorelbine from 77,851 EUR less in the first year, 158,611 EUR
in the second and 237,785 EUR in the third year. Cumulative three-year savings
with vinorelbine introduction to the CNHI PDL are 474,321 EUR. CONCLUSIONS:
The inclusion of vinorelbine to national reimbursement list for patients with non-
small lung cancer demonstrates significant savings and for patients provides ad-
ditional clinical benefits as a new treatment option.
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OBJECTIVES: In the treatment of locally advanced and metastasized stage of non-
small cell lung cancer (NSCLC), the first line of medication is comprised of a com-
bination of cisplatin and gemcitabine. The second line of treatment is the combi-
nation of carboplatin and paclitaxel, and the third line is pure erlotinib. A new
treatment scenario has been designed which uses the new medication, gefitinib,
that acts as an inhibitor of the epidermal growth factor receptor tyrosine-kinase
(EGFR-TK), which blocks growth signals and prevents the subsistence of cancer
cells. The aim of this study is to assess the potential financial impact of the intro-
duction of gefitinib into the treatment of metastasized NSCLC. METHODS: The
study conducted a budget impact analysis, which was meant to determine the
difference in cost between the treatment with gefitinib and the established treat-
ment, so as to provide justification for the introduction of the new drug. RESULTS:
Direct costs per patient with a proven positive EGFR mutation (5%) treated with the
new drug gefitinib, amount to 171.194,00 HRK, while costs for other patients treated
with the established medication, amount to 168.793,90 HRK, which shows that the
total cost for the new treatment scenario is somewhat higher. The total direct cost
for an established treatment scenario is 139.236.532, 10 HRK, while the new sce-
nario amounts to 142.270.005,50 HRK. Scientific observations point to the fact that
gefitinib has a higher drug tolerance and better effectiveness among patients diag-
nosed with an EGFR mutation. CONCLUSIONS: A budget impact analysis shows
that 28 patients will be treated with gefitinib in the year 2012, and 96 in the year
2014, which will increase the budget impact by 3%. However, a lowering in admin-
istration, patient monitoring and side-effects treatment costs are expected, mak-
ing the total budget impact of the gefitinib introduction into treatments practically
neutral (0,07%).
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OBJECTIVES: Oncology treatments are often expensive and result in toxicities
while not all patients may experience palliative or survival benefits. A growing
trend is to utilize biomarkers to better identify treatment responders. In this study,
the clinical and economic impact of biomarker testing in advanced non-small cell
lung cancer (NSCLC) treatment was explored. METHODS: A simulation model that
followed NSCLC patients from start of an investigational treatment, through dis-
ease progression and death was developed. The model assessed several biomarker
strategies including timing of biomarker assessments and predictive value of the
test categorized as true positive (remain on drug), false positive (remain on drug but
receive no benefit) and test negative (assume physicians withdrew treatment).
Drug related toxicities were defined as immediate or delayed onset to account for
differences over time. Disease progression and survival were based on published
trials. A hazard ratio of 0.8 for survival and an assumed cost of $60,000 with the
investigational agent over standard of care were used. Costs were from US public
available sources. Key model outcomes include costs, progression free survival
(PFS), overall survival (OS) and quality adjusted survival. RESULTS: The biomarker
strategy reduced the cost of treatment while providing PFS and OS similar to the
non-biomarker group. A reduction in total costs of 15% was seen, mainly in treat-
ment costs reductions. The biomarker strategy resulted in a 9% improvement in
quality adjusted survival due to fewer toxicities associated with avoided nonre-
sponsive treatment. The results vary depending on the accuracy of the test with a
trade-off in early testing being less accurate but accruing less treatment costs.
CONCLUSIONS: Accurate biomarker tests will not only provide clinical benefit, but
significantly reduce the economic burden of payers. It is important to further ex-
plore biomarker tests in the economic evaluation of oncology treatments.
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OBJECTIVES: In 2010, there were estimated to be in excess of 75,000 Herceptin IV
infusions in England, putting ever-increasing demands on hospital resource. This
analysis aims to estimate the change in resource use and subsequent time and cost
savings that could result from using Herceptin SC in three different English set-
tings; (1) hospital, (2) community and (3) patient self-administration at home ver-
sus Herceptin IV in the hospital. METHODS: Routine data on Herceptin IV-related
hospital use and processes was collected using the Chemotherapy Capacity Plan-
ning Tool. Interviews were conducted with a number of English centres in order to
determine likely changes to key delivery inputs as a result of using Herceptin SC.
An economic model was developed to estimate average time and cost savings from
delivering Herceptin SC in the three settings assuming 200 patients are given a full
treatment course of Herceptin and the capacity of a hospital is 10 IV chairs running
2 full days Herceptin clinics per week. Unit costs were taken from the Personal
Social Service Research Unit. RESULTS: A 100% switch of 200 Herceptin patients to
SC leads to a fall in total expenditure of £271,000, £1,200,000 and £1,500,000 in
settings (1), (2), and (3) respectively. This is largely due to reductions in resource
costs from 2,937 hours of IV chair time saved in all settings, 2,691 nurse hours saved
in (1) and (2) and 5,712 in (3), and 2,102 pharmacist technician hours saved in (1) and
(2) and 4,532 in (3).CONCLUSIONS:A switch from hospital-based IV to SC Herceptin
leads to substantial time and cost savings whether delivered in the hospital, in the
community or via patient self-administration. Therefore if Herceptin patients re-
ceived SC administration instead of IV, this could potentially increase hospitals’
throughput and overall efficiency. Any savings could be reinvested elsewhere in
order to improve overall patient care.
A415V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
